Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


| Molecular Weight | 358.27 g/mol |
|---|---|
| Molecular Formula | C15H13F3N2O5 |
| XLogP3 | -1.8 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Exact Mass | 358.07765601 g/mol |
| Monoisotopic Mass | 358.07765601 g/mol |
| Topological Polar Surface Area | 119 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 590 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Details:
Poractant Alfa is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Respiratory Distress Syndrome, Newborn.
Lead Product(s): L-Alfa-Glu-Afc,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Undisclosed
Sponsor: Chiesi Group
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 23, 2023

Lead Product(s) : L-Alfa-Glu-Afc,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Prophylactic Minimally Invasive Surfactant Evaluation
Details : Poractant Alfa is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Respiratory Distress Syndrome, Newborn.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 23, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Curosurf (Poractant Alfa) is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome.
Lead Product(s): L-Alfa-Glu-Afc,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Curosurf
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 06, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : L-Alfa-Glu-Afc,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (...
Details : Curosurf (Poractant Alfa) is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : Curosurf
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 06, 2020

Details:
Poractant Alfa is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Defects, Congenital.
Lead Product(s): L-Alfa-Glu-Afc,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Chiesi Group
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 29, 2019

Lead Product(s) : L-Alfa-Glu-Afc,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy
Details : Poractant Alfa is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Defects, Congenital.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 29, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Curosurf (Poractant Alfa) is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome, Newborn.
Lead Product(s): L-Alfa-Glu-Afc,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Curosurf
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 01, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : L-Alfa-Glu-Afc,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm N...
Details : Curosurf (Poractant Alfa) is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome, Newborn.
Product Name : Curosurf
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 01, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Curosurf (Poractant Alfa) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Distress Syndrome.
Lead Product(s): L-Alfa-Glu-Afc,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Curosurf
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : L-Alfa-Glu-Afc,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Admini...
Details : Curosurf (Poractant Alfa) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : Curosurf
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 13, 2016

Details:
Beractant is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Respiratory Distress Syndrome.
Lead Product(s): Beractant,L-Alfa-Glu-Afc
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Sponsor: Cornerstone Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 23, 2012

Lead Product(s) : Beractant,L-Alfa-Glu-Afc
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Cornerstone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Beractant is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 23, 2012

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Market Place
ABOUT THIS PAGE
32
PharmaCompass offers a list of L-Alfa-Glu-Afc API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right L-Alfa-Glu-Afc manufacturer or L-Alfa-Glu-Afc supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred L-Alfa-Glu-Afc manufacturer or L-Alfa-Glu-Afc supplier.
PharmaCompass also assists you with knowing the L-Alfa-Glu-Afc API Price utilized in the formulation of products. L-Alfa-Glu-Afc API Price is not always fixed or binding as the L-Alfa-Glu-Afc Price is obtained through a variety of data sources. The L-Alfa-Glu-Afc Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A L-Alfa-Glu-Afc manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of L-Alfa-Glu-Afc, including repackagers and relabelers. The FDA regulates L-Alfa-Glu-Afc manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. L-Alfa-Glu-Afc API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of L-Alfa-Glu-Afc manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A L-Alfa-Glu-Afc supplier is an individual or a company that provides L-Alfa-Glu-Afc active pharmaceutical ingredient (API) or L-Alfa-Glu-Afc finished formulations upon request. The L-Alfa-Glu-Afc suppliers may include L-Alfa-Glu-Afc API manufacturers, exporters, distributors and traders.
click here to find a list of L-Alfa-Glu-Afc suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
L-Alfa-Glu-Afc Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of L-Alfa-Glu-Afc GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right L-Alfa-Glu-Afc GMP manufacturer or L-Alfa-Glu-Afc GMP API supplier for your needs.
A L-Alfa-Glu-Afc CoA (Certificate of Analysis) is a formal document that attests to L-Alfa-Glu-Afc's compliance with L-Alfa-Glu-Afc specifications and serves as a tool for batch-level quality control.
L-Alfa-Glu-Afc CoA mostly includes findings from lab analyses of a specific batch. For each L-Alfa-Glu-Afc CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
L-Alfa-Glu-Afc may be tested according to a variety of international standards, such as European Pharmacopoeia (L-Alfa-Glu-Afc EP), L-Alfa-Glu-Afc JP (Japanese Pharmacopeia) and the US Pharmacopoeia (L-Alfa-Glu-Afc USP).